Drug Trial Radar · NCT06504732
To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer
Last checked: Nov 19, 2026Latest source record: Jun 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
574
Planned (sponsor's estimate)
Start
Aug 15, 2024
Primary completion
Jul 2028
Study completion Jul 2029
Sponsor
- Lead sponsor
- SUNHO(China)BioPharmaceutical CO., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 17, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The safety, tolerability, and determination of the maximum tolerated dose (MTD) of the combination therapy were first evaluated for IAH0968 in combination with or without the CAPEOX regimen in unsystematically treated subjects with HER2-expressing advanced/metastatic colorectal or gastric cancers (including adenocarcinomas of the gastro-esophageal junction) or HER2-hypo-expressing advanced/metastatic solid tumors. The efficacy of IAH0968 in combination with the CAPEOX regimen versus trastuzumab in combination with the CAPEOX regimen in subjects with HER2-positive advanced/metastatic gastric cancer, including gastro-esophageal junction adenocarcinoma, was then assessed by progression-free survival (PFS) and OS according to the Research and Evaluation Criteria for the Evaluation of Efficacy in Solid Tumors (RECIST) 1.1.
Conditions
- Stomach Neoplasms
- Solid Tumor
Interventions
IAH0968Drug
Experimental:IAH0968 15 mg/kg on Day 1 of each 3-week cycle as an IV infusion. Drug: Oxaliplatin 130 mg/m\^2 on Day 1 of each 3-week cycle over 2 hours as an IV infusion, administered as part of CAPOX chemotherapy regimen. Drug: Capecitabine 1000 mg/m\^2 as oral capsules BID on Days 1-14 of each 3-week cycle, administered as part of CAPOX chemotherapy regimen.
Trastuzumab InjectionDrug
Active Comparator: Trastuzumab 8 mg/kg loading dose and then 6 mg/kg maintenance dose administered IV on day 1 of each 3-week cycle. Drug: Oxaliplatin 130 mg/m\^2 on Day 1 of each 3-week cycle over 2 hours as an IV infusion, administered as part of CAPOX chemotherapy regimen. Drug: Capecitabine 1000 mg/m\^2 as oral capsules BID on Days 1-14 of each 3-week cycle, administered as part of CAPOX chemotherapy regimen.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experienced At Least One Adverse Event (AE)Time frame: Up to approximately 48 months
- Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)Time frame: Up to approximately 48 months
- Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)Time frame: Up to approximately 48 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China · Recruiting
The First Hospital of China Medical University
Shenyang, Liaoning, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.